888-416-9305 info@abterrabio.com

Digital Proteomics is now Abterra Biosciences

Abterra Biosciences discovers fully human antibodies from patients

Truly human antibody therapeutics.

Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.

Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!

Abterra Bio Reptor Hybridoma Sequencing

REPTOR™  

Next-Gen Sequencing Hybridoma

Abterra Bio Reptor Bulk B Cell Sequencing

REPTOR™  

Next-Gen Sequencing Bulk B Cells
Abterra Bio Reptor Hit Expansion

REPTOR™  

Next-Gen Sequencing Hit Expansion 
Abterra Bio Reptor Library Sequencing

REPTOR™  

Next-Gen Sequencing Display Library
Abterra Bio Alicanto Rabbit Antibody Discovery

ALICANTO®

Rabbit Monoclonal Antibody Discovery
Abterra Bio Alicanto Single Domain Antibody Discovery

ALICANTO®  

Single Domain (VHH) Antibody Discovery

Abterra Bio Alicanto Human Antibody Discovery

ALICANTO®

Human Antibody Discovery
Abterra Bio Valens Sequence Confirmation

VALENS™

Protein Sequence Confirmation
Abterra Bio Valens Antibody Protein Sequencing

VALENS™  

Antibody Protein Sequencing

Our partners’ success means everything to us

I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.

Sandeep Kumar, PhD

Associate Director - Antibody Discovery & Engineering, Scholar Rock

Latest News

PEGS Boston Summit 2021 Presentation

Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses.  The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been analyzed in a small number of studies. ...

Abterra Bio Seattle Angel Conference Winner

We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...

Digital Proteomics is Abterra Biosciences

We're excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it's time to realign our name with our capabilities; we have developed core technologies that are driving our partners' antibody discovery...

We are a CONNECT Cool Company 2021!

We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...

Scientific Updates

A Decade of De Novo Antibody Sequencing Experience

De novo antibody sequencing experience Have you lost your hybridoma? Is your hybridoma no longer producing? Is your hybridoma producing more than your desired antibody? Do you have a monoclonal antibody from a clinical sample, but no way to recover the source B cell?...

Immune Repertoire Sequencing in Human

Immune repertoire sequencing enables deeper understanding of the adaptive immune response [1].  Abterra Biosciences has developed Reptor™, a flexible immune repertoire sequencing and analysis service. In this study, we analyzed the B-cell receptor (BCR) repertoire...

Clonal Hit-Expansion Case Study

Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign.  Contact us to learn more about how our...

Social Media Posts

Meet @necastellana! The UCSD CSE graduate and CEO of @AbterraBio believed that computer science, in conjunction with other scientific fields, had a critical role to play in ameliorating the global health crisis.

Read her feature story : https://bit.ly/3ANcAcl

Don’t miss the chance to recover your lost hybridoma for free!! Sign up for our case study: https://lnkd.in/gm8H8diy
Read more on our de novo sequencing approach and how it can be used to solve your problem!
#biopharma #sequencing
https://abterrabio.com/2018/08/06/de-novo-antibody-sequencing-an-overview/

Load More...

Every day, we strive to help our partners and collaborators push the boundaries of their science.

Subscribe To Our Newsletter!

Don't miss out on the latest case studies, posters, and other news.

You have Successfully Subscribed!